Trial Profile
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 12 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2017 Planned End Date changed from 1 Jan 2017 to 31 Jan 2019.